Pervasis Therapeutics
Biotech Specialty Pharma
One Kendall Square, Building 600, 2nd Floor
Cambridge, MA 02139 USA
phone: 617.621.3407
fax: 617-621-3408
Symbol Private
Founded 0
Employees
www.pervasistx.com
Research Sector Biotech Specialty Pharma
Summary Description
Biologically active vascular interventions to treat cardiovascular disorders.
Management
Stephen A. Bollinger, President & COO; Helen Marie Nugent, Ph.D., Senior Director, Product Development; Jack Harvey, M.S., Director, Manufacturing; Laurie A. Ridener, R.A.C., Director, Regulatory Affairs; John L. Wilson, Director, Clinical Operations
Keywords
biologically active vascular interventions, cardiovascular, vascular failure, peripheral bypass failure

Comment | Printable Version | Apr. 06, 2007
If you work for Pervasis Therapeutics and want to update this profile, click here


Description
Pervasis Therapeutics directs its energies towards creating biologically active vascular interventions to treat significant unmet needs in cardiovascular disease.
Products / Services
Their lead product is a novel therapy to reverse acute vascular injury in a number of clinical settings, including vascular failure and peripheral bypass failure.
Funding
The company raised its Series B financing in 2005 to fund preclinical development and initiate clinical trials in two vascular indications.


2008-11-21-298